PET and MRI Imaging With Scopolamine at the Muscarinic M1 Receptor

Inclusion Criteria: * Willing and able to give voluntary, written informed consent * Have the ability to read and write, communicate effectively with the investigator and to comply with all study requirements, restrictions, and directions of the research staff. * Male or female, aged Age 18 to 60 years inclusive, at screening. * In good general health as evidenced by medical history, physical examination, ECG, serum/urine biochemistry, hematology, and serology tests. Exclusion Criteria: * History or presence of clinically significant respiratory, GI, renal, hepatic, pancreatic, hematological, neurological (including history of seizure), cardiovascular, psychiatric (including known addictive disorders), musculoskeletal, genitourinary, immunological, or dermatological disorders, including all cancers. * Laboratory tests with clinically significant abnormalities or positive urine toxicology, at screening. * Abnormal and clinically significant ECG, as (as determined by the Investigator or his/her designee) at screening. * Seropositive for hepatitis B, hepatitis C, and/or HIV * Pregnancy or lactation * Use of prescription medications within 14 days of scopolamine dosing. Exceptions may be allowed only if the medication's administration is deemed unlikely to impact the study result. * Current or recent use (within 14 days) of scopolamine transdermal patch, for any reason (ex: for motion sickness). * Use of drugs with anticholinergic properties within 14 days of scopolamine dosin…